SCHEMBL6490853

SCHEMBL6490853

CCOC(=O)/C1=C(\c2ccc(C)cc2)CCCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 14/20 0.55
SLC6A2 P23975 11/20 0.55
SLC6A4 P31645 4/20 0.55
CHRM2 P08172 3/20 0.46
CHRM4 P08173 3/20 0.46
CHRM5 P08912 3/20 0.46
CHRM1 P11229 3/20 0.46
CHRM3 P20309 3/20 0.46
CACNB4 O00305 1/20 0.45
CACNA1A O00555 1/20 0.45
CACNA1G O43497 1/20 0.45
CACNG3 O60359 1/20 0.45
CACNA1F O60840 1/20 0.45
CACNA1H O95180 1/20 0.45
ACHE P22303 1/20 0.45
CACNB3 P54284 1/20 0.45
CACNA2D1 P54289 1/20 0.45
CACNG7 P62955 1/20 0.45
CACNA1B Q00975 1/20 0.45
CACNA1D Q01668 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490857 1.00 SLC6A3 (0.55) SLC6A3SLC6A2SLC6A4CHRM2CHRM4
SCHEMBL6489548 0.89 SLC6A3 (0.54) SLC6A3SLC6A2SLC6A4CHRM2CHRM4
SCHEMBL21332404 0.88 SLC6A3 (0.72) SLC6A3SLC6A2SLC6A4CHRM5CHRM1
SCHEMBL1752641 0.88 SLC6A2 (0.67) SLC6A3SLC6A2SLC6A4CHRM2CHRM4
SCHEMBL1752640 0.88 SLC6A2 (0.67) SLC6A3SLC6A2SLC6A4CHRM2CHRM4
SCHEMBL1743636 0.87 SLC6A3 (0.71) SLC6A3SLC6A2SLC6A4CHRM5CHRM1
SCHEMBL16061721 0.86 SLC6A3 (0.64) SLC6A3SLC6A2SLC6A4CHRM2CHRM4
SCHEMBL6503784 0.85 SLC6A2 (0.56) SLC6A3SLC6A2SLC6A4CHRM2CHRM4
SCHEMBL6503781 0.85 SLC6A2 (0.56) SLC6A3SLC6A2SLC6A4CHRM2CHRM4
SCHEMBL6503574 0.84 SLC6A3 (0.75) SLC6A3SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 SLC6A3 3942/4885SLC6A2 1801/4885SLC6A4 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.